Canadian Real‐World Outcomes of Omnipod Initiation in People with Type 1 Diabetes (COPPER study): Evidence from the LMC Diabetes Registry
Open Access
- 11 October 2020
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 38 (6) , e14420
Abstract
Aims: To investigate real‐world clinical outcomes in adults with type 1 diabetes who initiated the Omnipod Insulin Management System (Insulet Corp., Acton, MA, USA) compared to a matched cohort who maintained multiple daily injection therapy.Methods: This retrospective observational study used data from the Canadian LMC Diabetes Registry. Adults with type 1 diabetes who switched from multiple daily injections to the Omnipod system as usual standard of care between January 2011 and April 2019 were matched to a cohort of adults with type 1 diabetes who maintained multiple daily injection therapy, using propensity‐score matching. The primary outcome was change in HbA1c at 3‐ to 6‐month follow‐up.Results: Propensity‐score matching resulted in a final analytical cohort of 286 individuals (143/cohort). HbA1c in the Omnipod cohort was reduced by a mean ± sd of –3 ± 10 mmol/mol (–0.2 ± 1.0%; P = 0.005) with no change in the MDI cohort [0 ± 10 mmol/mol (0.0 ± 1.0%); P = 0.74]. HbA1c change was seen only in persons with baseline HbA1c ≥75 mmol/mol (≥9.0%) [Omnipod cohort: –15 ± 12 mmol/mol (–1.4 ± 1.1%); P < 0.001] with a between‐treatment difference [mean (95% CI)] of –12 (–18, –6) mmol/mol [–1.1 (–1.6, –0.5) %, P < 0.001]. The median total daily dose of insulin was lower following Omnipod initiation (baseline 0.63 U/kg vs follow‐up 0.53 U/kg; P < 0.001), with no change in the MDI cohort (baseline 0.68 U/kg vs follow‐up 0.67 U/kg; P = 0.23).Conclusions: Adults with type 1 diabetes who initiated use of the Omnipod system in a real‐world clinical setting had lower HbA1c and total daily dose of insulin at 3‐ to 6‐month follow‐up compared to a matched cohort of adults who maintained multiple daily injection therapy. A treatment difference in HbA1c change was seen only in people with baseline HbA1c ≥ 75 mmol/mol (9.0%). (Clinical trials registration: NCT04226378).Keywords
Funding Information
- Insulet Corporation
This publication has 9 references indexed in Scilit:
- State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018Diabetes Technology & Therapeutics, 2019
- Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily PracticeDiabetes Technology & Therapeutics, 2018
- Long-term study of tubeless insulin pump therapy compared to multiple daily injections in youth with type 1 diabetes: Data from the German/Austrian DPV registryPediatric Diabetes, 2018
- Specialist-Led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C)Diabetes Care, 2016
- Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysisEndocrine, 2016
- Changes in HbA1c and Weight Following Transition to Continuous Subcutaneous Insulin Infusion Therapy in Adults With Type 1 DiabetesJournal of Diabetes Science and Technology, 2016
- Efficacy of the Omnipod Insulin Management System on Glycemic Control in Patients With Type 1 Diabetes Previously Treated With Multiple Daily Injections or Continuous Subcutaneous Insulin InfusionJournal of Diabetes Science and Technology, 2016
- Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 DiabetesDiabetes Technology & Therapeutics, 2016
- Specialist‐led diabetes registries and predictors of poor glycemic control in type 2 diabetes: Insights into the functionally refractory patient from the LMC Diabetes Registry databaseJournal of Diabetes, 2015